Maruf Abdullah Al, Bousman Chad A
Rady Faculty of Health Sciences, College of Pharmacy University of Manitoba Winnipeg Manitoba Canada.
Children's Hospital Research Institute of Manitoba Winnipeg Manitoba Canada.
PCN Rep. 2022 Jun 22;1(2):e26. doi: 10.1002/pcn5.26. eCollection 2022 Jun.
Pharmacogenetic (PGx) testing has emerged as a tool for predicting a person's ability to process and react to drugs. Despite the growing evidence-base, enthusiasm, and successful efforts to implement PGx testing in psychiatry, a consensus on how best to implement PGx testing into practice has not been established and numerous hurdles to widespread adoption remain to be overcome. In this article, we summarize the most used approaches and commonly encountered hurdles when implementing PGx testing into routine psychiatric care. We also highlight effective strategies that have been used to overcome hurdles. These strategies include the development of user-friendly clinical workflows for test ordering, use, and communication of results, establishment of test standardization and reimbursement policies, and development of tailored curriculums for educating health-care providers and the public. Although knowledge and awareness of these approaches and strategies to overcome hurdles alone may not be sufficient for successful implementation, they are necessary to ensure the effective spread, scale, and sustainability of PGx testing in psychiatry and other areas of medicine.
药物遗传学(PGx)检测已成为一种预测个体对药物进行处理和反应能力的工具。尽管有越来越多的证据基础、热情以及在精神病学领域实施PGx检测的成功努力,但对于如何最好地将PGx检测应用于实践尚未达成共识,广泛采用仍面临诸多障碍有待克服。在本文中,我们总结了将PGx检测纳入常规精神科护理时最常用的方法和常见障碍。我们还强调了用于克服障碍的有效策略。这些策略包括开发便于用户操作的临床工作流程,用于检测的订购、使用和结果沟通,建立检测标准化和报销政策,以及开发量身定制的课程以教育医疗保健提供者和公众。尽管仅了解这些克服障碍的方法和策略可能不足以成功实施,但它们对于确保PGx检测在精神病学和其他医学领域的有效推广、扩大规模和可持续性是必要的。